Hyperhomcysteinemia - The biochemical link between a weak heart and brittle bones?

Clinical Laboratory

Volumn 52, Issue 3-4, 2006, Pages 137-147

  Herrmann, Markus ^a   Taban Shomal, Omid ^a   Müller, Stefanie ^a   Gunter, Laureen ^a   Hübner, Ulrich ^a   Böhm, Michael ^a   Herrmann, Wolfgang ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Bone; Fracture; Heart failure; Homocysteine; Myocardium; Osteoporosis

Indexed keywords

BIOCHEMICAL MARKER; CYANOCOBALAMIN; ETIDRONIC ACID; FOLIC ACID; HOMOCYSTEINE; MECOBALAMIN; METHOTREXATE; PLACEBO; PYRIDOXINE;

BIOCHEMISTRY; BONE METABOLISM; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; GERIATRIC PATIENT; HEART FAILURE; HIP FRACTURE; HUMAN; HYPERHOMOCYSTEINEMIA; NONHUMAN; OSTEOPOROSIS; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; VITAMIN DEFICIENCY; ANIMAL; CONGESTIVE HEART FAILURE; DISEASE MODEL; METABOLISM; PATHOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; HEART FAILURE, CONGESTIVE; HUMANS; HYPERHOMOCYSTEINEMIA; OSTEOPOROSIS; RISK FACTORS;

EID: 33645568376     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (166)

1. O'Connell JB, Bristow MR. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant 1994;13:S107-S112.
2. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J 1991;121:951-7.
3. Kannel WB. Epidemiology and prevention of cardiac failure: Framingham Study insights. Eur Heart J 1987;8 Suppl F:23-6.
4. Walker-Bone K, Walter G, Cooper C. Recent developments in the epidemiology of osteoporosis. Curr Opin Rheumatol 2002; 14:411-5.
5. Melton LJ, III. Adverse outcomes of osteoporotic fractures in the general population. J Bone Miner Res 2003;18:1139-41.
6. Chrischilles E, Shireman T, Wallace R. Costs and health effects of osteoporotic fractures. Bone 1994;15:377-86.
7. Kanis JA, Johnell O, Oden A, De Laet C, Mellstrom D. Epidemiology of osteoporosis and fracture in men. Calcif Tissue Int 2004;75:90-9.
8. Kanis JA, Jonsson B. Economic evaluation of interventions for osteoporosis. Osteoporos Int 2002;13:765-7.
9. Straus SE. Geriatric medicine. BMJ 2001;322:86-9.
10. Brody JA, Grant MD. Age-associated diseases and conditions: implications for decreasing late life morbidity. Aging (Milano) 2001;13:64-7.
11. Nishio K, Mukae S, Aoki S, Itoh S, Konno N, Ozawa K et al. Congestive heart failure is associated with the rate of bone loss. J Intern Med 2003;253:439-46.
12. Davutoglu V, Kervancioglu S, Sezen Y, Gunay N. A case of massive dystrophic cardiac calcinosis with increased bone resorption markers: a novel pathophysiologic link? Cardiol Rev 2004;12:306-8.
13. Cleland JG, Khand A, Clark A. The heart failure epidemic: exactly how big is it? Eur Heart J 2001;22:623-6.
14. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115-40.
15. Mosterd A, Hoes AW, de Bruyne MC, Deckers JW, Linker DT, Hofman A, Grobbee DE. Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study. Eur Heart J 1999;20:447-55.
16. Bleumink GS, Knetsch AM, Sturkenboom MC, Straus SM, Hofman A, Deckers JW et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J 2004:25:1614-9.
17. McDonagh TA, Morrison CE, Lawrence A, Ford I, Tunstall-Pedoe H, McMurray JJ, Dargie HJ. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 1997;350:829-33.
18. Ceia F, Fonseca C, Mota T, Morais H, Matias F, de SA, Oliveira A. Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. Eur J Heart Fail 2002;4:531-9.
19. Cohen-Solal A, Desnos M, Delahaye F, Emeriau JP, Hanania G. A national survey of heart failure in French hospitals. The Myocardiopathy and Heart Failure Working Group of the French Society of Cardiology, the National College of General Hospital Cardiologists and the French Geriatrics Society. Eur Heart J 2000;21:763-9.
20. Jaarsma T, Haaijer-Ruskamp FM, Sturm H, Van Veldhuisen DJ. Management of heart failure in The Netherlands. Eur J Heart Fail 2005;7:371-5.
21. Hedberg P, Lonnberg I, Jonason T, Nilsson G, Pehrsson K, Ringqvist I. Left ventricular systolic dysfunction in 75-year-old men and women; a population-based study. Eur Heart J 2001;22: 676-83.
22. Kanis JA, Black D, Cooper C, Dargent P, wson-Hughes B, De Laet C et al. A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int 2002;13:527-36.
23. Eisman J, Clapham S, Kehoe L. Osteoporosis prevalence and levels of treatment in primary care: the Australian BoneCare Study. J Bone Miner Res 2004;19:1969-75.
24. Hodgson SF, Watts NB, Bilezikian JP, Clarke BL, Gray TK, Harris DW et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 2003;9:544-64.
25. Herrmann M, Taban-Shomal O, Hübner U, Böhm M, and Herrmann W. A Review of Homocysteine and Heart Failure. Eur J Heart Fail. 2006. Ref Type: In Press
26. Herrmann M, Widmann T, Herrmann W. Homocysteine - a newly recognised risk factor for osteoporosis. Clin Chem Lab Med 2005;43:1111-7.
27. Vasan RS, Beiser A, D'Agostino RB, Levy D, Selhub J, Jacques PF et al. Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. JAMA 2003;289:1251-7.
28. van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, van der KM, de JR, Lindemans J et al. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 2004;350:2033-41.
29. McLean RR, Jacques PF, Selhub J, Tucker KL, Samelson EJ, Broe KE et al. Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 2004;350:2042-9.
30. McKusick VA. Heritable disorders of connective tissue. St. Louis: C.V. Mosby, 1966:155pp.
31. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56:111-28.
32. Kraus JP, Janosik M, Kozich V, Mandell R, Shih V, Sperandeo MP et al. Cystathionine beta-synthase mutations in homocystinuria. Hum Mutat 1999;13:362-75.
33. McKusick V. Heritable disorders of connective tissue, 3 ed. St Louis: C.V.Mosby, 2004:150pp.
34. Mudd SH, Havlik R, Levy HL, McKusick VA, Feinleib M. A study of cardiovascular risk in heterozygotes for homocystinuria. Am J Hum Genet 1981;33:883-93.
35. Wilcken DE, Reddy SG, Gupta VJ. Homocysteinemia, ischemic heart disease, and the carrier state for homocystinuria. Metabolism 1983;32:363-70.
36. Schedewie H, Willich E, Grobe H, Schmidt H, Muller KM. Skeletal fingings in homocystinuria: a collaborative study. Pediatr Radiol 1973;1:12-23.
37. Brenton DP. Skeletal abnormalities in homocystinuria. Postgrad Med J 1977;53:488-96.
38. Parrot F, Redonnet-Vernhet I, Lacombe O, Gin H. Osteoporosis in late-diagnosed adult homocystinuric patients. J Inherit Metab Dis 2000;23:338-40.
39. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 1985; 37:1-31.
40. Wilcken DE, Reddy SG, Gupta VJ. Homocysteinemia, ischemic heart disease, and the carrier state for homocystinuria. Metabolism 1983;32:363-70.
41. Wilcken DE, Dudman NP, Tyrrell PA, Robertson MR. Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: possible implications for prevention of vascular disease. Metabolism 1988;37:697-701.
42. Wilcken DE, Dudman NP. Mechanisms of thrombogenesis and accelerated atherogenesis in homocysteinaemia. Haemostasis 1989;19 Suppl 1:14-23:14-23.
43. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996;27:517-27.
44. Boers GH. Hyperhomocysteinaemia: a newly recognized risk factor for vascular disease. Neth J Med 1994;45:34-41.
45. Robinson K, Mayer E, Jacobsen DW. Homocysteine and coronary artery disease. Cleve Clin J Med 1994;61:438-50.
46. Malinow MR. Homocyst(e)ine and arterial occlusive diseases 1. J Intern Med 1994;236:603-17.
47. Meleady RA, Graham IM. Homocysteine as a risk factor for coronary artery disease. J Cardiovasc Risk 1995;2:216-21.
48. Blacher J, Demuth K, Guerin AP, Vadez C, Moatti N, Safar ME, London GM. Association between plasma homocysteine concentrations and cardiac hypertrophy in end-stage renal disease. J Nephrol 1999;12:248-55.
49. Poyrazoglu HM, Dusunsel R, Narin F, Gunduz Z, Narin N, Karakukcu M, Tahan F. Homocysteine and left ventricular hypertrophy in children with chronic renal failure. Pediatr Nephrol 2004;19:193-8.
50. Wocial B, Berent H, Kostrubiec M, Kuczynska K, Kuch-Wocial A, Nieweglowska N. Homocysteine, adrenergic activity and left ventricular mass in patients with essential hypertension. Blood Press 2002;11:201-5.
51. Cooke GE, Eaton GM, Whitby G, Kennedy RA, Binkley PF, Moeschberger ML, Leier CV. Plasma atherogenic markers in congestive heart failure and posttransplant (heart) patients. J Am Coll Cardiol 2000;36:509-16.
52. Ventura P, Panini R, Verlato C, Scarpetta G, Salvioli G. Hyperhomocysteinemia and related factors in 600 hospitalized elderly subjects. Metabolism 2001;50:1466-71.
53. Ueland PM, Nygard O, Vollset SE, Refsum H. The Hordaland Homocysteine Studies. Lipids 2001;36 Suppl:S33-9.:S33-S39.
54. Herrmann M, Kindermann I, Muller S, Georg T, Kindermann M, Bohm M, Herrmann W. Relationship of plasma homocysteine with the severity of chronic heart failure. Clin Chem 2005; 51:1512-5.
55. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-60.
56. Schofield RS, Wessel TR, Walker TC, Cleeton TS, Hill JA, Aranda JM, Jr. Hyperhomocysteinemia in patients with heart failure referred for cardiac transplantation: preliminary observations. Clin Cardiol 2003;26:407-10.
57. Finkelstein JD. The metabolism of homocysteine: pathways and regulation. Eur J Pediatr 1998;157 Suppl 2:S40-S44.
58. Finkelstein JD, Martin JJ. Homocysteine. Int J Biochem Cell Biol 2000;32:385-9.
59. Stanger O, Herrmann W, Pietrzik K, Fowler B, Geisel J, Dierkes J, Weger M. DACH-LIGA Homocystein German, Austria and Swiss Homocysteine Society): Concensus Paper on the Rational Clinical Use of Homocysteine, Folic Acid and B Vitamins in Cardiovascular and Thrombotic Diseases: Guidlines and Recommendations. Clin Chem Lab Med 2003;41:1392-403.
60. Refsum H, Smith AD, Ueland PM, Nexo F, Clarke R, McPartlin J et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem 2004;50:3-32.
61. Gorelik O, moznino-Sarafian D, Feder I, Wachsman O, Alon I, Litvinjuk V et al. Dietary intake of various nutrients in older patients with congestive heart failure. Cardiology 2003;99:177-81.
62. Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, Jacobsen SJ. Trends in heart failure incidence and survival in a community-based population. JAMA 2004;292:344-50.
63. Herzlich BC, Lichstein E, Schulhoff N, Weinstock M, Pagala M, Ravindran K et al. Relationship among homocyst(e)ine, vitamin B-12 and cardiac disease in the elderly: association between vitamin B-12 deficiency and decreased left ventricular ejection fraction. J Nutr 1996;126:1249S-53S.
64. Suliman ME, Qureshi AR, Barany P, Stenvinkel P, Filho JC, Anderstam B et al. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int 2000;57:1727-35.
65. Suliman ME, Lindholm B, Barany P, Bergstrom J. Hyperhomocysteinemia in chronic renal failure patients: relation to nutritional status and cardiovascular disease. Clin Chem Lab Med 2001;39:734-8.
66. Friedman AN, Bostom AG, Selhub J, Levey AS, Rosenberg IH. The kidney and homocysteine metabolism. J Am Soc Nephrol 2001;12:2181-9.
67. Herrmann W, Schorr H, Obeid R, Makowski J, Fowler B, Kuhlmann MK. Disturbed homocysteine and methionine cycle intermediates s-adenosylhomocysteine and s-adenosylmethionine are related to degree of renal insufficiency in type 2 diabetes. Clin Chem 2005;51:891-7.
68. Stam F, van GC, ter Wee PM, Kulik W, Smith DE, Jakobs C et al. Homocysteine clearance and methylation flux rates in health and end-stage renal disease: association with S-adenosylhomocysteine. Am J Physiol Renal Physiol 2004;287:F215-F223.
69. Bibbins-Domingo K, Lin F, Vittinghoff E, Barrett-Connor F, Grady D, Shlipak MG. Renal insufficiency as an independent predictor of mortality among women with heart failure. J Am Coll Cardiol 2004;19;44:1593-600.
70. Shlipak MG, Massie BM. The clinical challenge of cardiorenal syndrome. Circulation 2004;110:1514-7.
71. Shlipak MG, Smith GL, Rathore SS, Massie BM, Krumholz HM. Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin intervention group trial. J Am Soc Nephrol 2004;15:2195-203.
72. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000;35:681-9.
73. Mahon NG, Blackstone EH, Francis GS, Starling RC, III, Young JB, Lauer MS. The prognostic value of estimated creatinine clearance alongside functional capacity in ambulatory patients with chronic congestive heart failure. J Am Coll Cardiol 2002; 40:1106-13.
74. Hillege HL, Girbes AR, de Kam PJ, Boomsma F, de ZD, Charlesworth A et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000;102:203-10.
75. Moustapha A, Naso A, Nahlawi M, Gupta A, Arheart KL, Jacobsen DW et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 1998;20;97:138-41.
76. Herrmann W, Schorr H, Geisel J, Riegel W. Homocysteine, cystathionine, methylmalonic acid and B-vitamins in patients with renal disease. Clin Chem Lab Med 2001;39:739-46.
77. Herrmann W, Obeid R. Hyperhomocysteinemia and Response of Methionine Cycle Intermediates to Vitamin Treatment in Renal Patients. Clin Chem Lab Med 2005;43:1039-47.
78. Guttormsen AB, Ueland PM, Svarstad E, Refsum H. Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney Int 1997;52:495-502.
79. Obeid R, Kuhlmann M, Kirsch CM, Herrmann W. Cellular uptake of vitamin B12 in patients with chronic renal failure. Nephron Clin Pract 2005;99:c42-c48.
80. Sundström j and Vasan, R. S. Homocysteine and heart failure. 43. 2005. Clin Chem Lab Med. Ref Type: Generic
81. Joseph J, Washington A, Joseph L, Koehler L, Fink LM, Hauer-Jensen M, Kennedy RH. Hyperhomocysteinemia leads to adverse cardiac remodeling in hypertensive rats. Am J Physiol Heart Circ Physiol 2002;283:H2567-H2574.
82. Joseph J, Joseph L, Shekhawat NS, Devi S, Wang J. Melchert RB et al. Hyperhomocysteinemia leads to pathological ventricular hypertrophy in normotensive rats. Am J Physiol Heart Circ Physiol 2003;285:H679-H686.
83. Walker E, Black J, Parris C, Bryda EC, Cansino S, Hunt L et al. Effect of experimental hyperhomocysteinemia on cardiac structure and function in the rat. Ann Clin Lab Sci 2004;34:175-80.
84. Kennedy RH, Owings R, Shekhawat N, Joseph J. Acute negative inotropic effects of homocysteine are mediated via the endothelium. Am J Physiol Heart Circ Physiol 2004:287:H812-H817.
85. Chen P, Poddar R, Tipa EV, DiBello PM, Moravec CD, Robinson K et al. Homocysteine metabolism in cardiovascular cells and tissues: implications for hyperhomocysteinemia and cardiovascular disease. Adv Enzyme Regul 1999:39:93-109.
86. Weiss N. Mechanisms of increased vascular oxidant stress in hyperhomocys-teinemia and its impact on endothelial function. Curr Drug Metab 2005;6:27-36.
87. Geisel J, Jodden V, Obeid R, Knapp JP, Bodis M, Herrmann W. Stimulatory effect of homocysteine on interleukin-8 expression in human endothelial cells. Clin Chem Lab Med 2003;41:1045-8.
88. Spinale FG, Coker ML, Bond BR, Zellner JL. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target. Cardiovasc Res 2000:46: 225-38.
89. Sakata Y, Yamamoto K, Mano T, Nishikawa N, Yoshida J, Hori M et al. Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of Angiotensin-converting enzyme inhibitor. Circulation 2004;109:2143-9.
90. Lee RT. Matrix metalloproteinase inhibition and the prevention of heart failure. Trends Cardiovasc Med 2001;11:202-5.
91. Li YY, Feldman AM. Matrix metalloproteinases in the progression of heart failure: potential therapeutic implications. Drugs 2001;61:1239-52.
92. Polyakova V, Hein S, Kostin S, Ziegelhoeffer T, Schaper J. Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression. J Am Coll Cardiol 2004;%19;44:1609-18.
93. Nishikawa N, Yamamoto K, Sakata Y, Mano T, Yoshida J, Miwa T et al. Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation. Cardiovasc Res 2003;57:766-74.
94. Yamazaki T, Lee JD, Shimizu H, Uzui H, Ueda T. Circulating matrix metalloproteinase-2 is elevated in patients with congestive heart failure. Eur J Heart Fail 2004:6:41-5.
95. Miller A, Mujumdar V, Palmer L, Bower JD, Tyagi SC. Reversal of endocardial endothelial dysfunction by folic acid in homocysteinemic hypertensive rats. Am J Hypertens 2002;15: 157-63.
96. Shastry S, Tyagi SC. Homocysteine induces metalloproteinase and shedding of beta-1 integrin in microvessel endothelial cells. J Cell Biochem 2004;93:207-13.
97. Bescond A, Augier T, Chareyre C, Garcon D, Hornebeck W, Charpiot P. Influence of homocysteine on matrix metalloproteinase-2: activation and activity. Biochem Biophys Res Commun 1999;263:498-503.
98. Stanger O, Weger M. Interactions of homocysteine, nitric oxide, folate and radicals in the progressively damaged endothelium. Clin Chem Lab Med 2003;41:1444-54.
99. Sato Y, Honda Y, Iwamoto J, Kanoko T, Satoh K. Effect of folate and mecobalamin on hip fractures in patients with stroke: a randomized controlled trial. JAMA 2005;293:1082-8.
100. WHO Study Group on assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Report of a WHO Study Group. WHO Technical Report Series 843. 1994. Ref Type: Abstract
101. Cagnacci A, Baldassari F, Rivolta G, Arangino S, Volpe A. Relation of homocysteine, folate, and vitamin B12 to bone mineral density of postmenopausal women. Bone 2003;33:956-9.
102. Golbahar J, Hamidi A, Aminzadeh MA, Omrani OR. Association of plasma folate, plasma total homocysteine, but not methylenetetrahydrofolate reductase C667T polymorphism, with bone mineral density in postmenopausal Iranian women: a cross-sectional study. Bone 2004:35:760-5.
103. Herrmann M, Kraenzlin M, Pape G, Sand-Hill M, Herrmann W. Relation between homocysteine and biochemical bone turnover markers and bone mineral density in pen- and post-menopausal women. Clin Chem Lab Med 2005;43:1118-23.
104. Morris MS, Jacques PF, Selhub J. Relation between homocysteine and B-vitamin status indicators and bone mineral density in older Americans. Bone 2005;37:234-42.
105. Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: scientific review. JAMA 2002;288:1889-97.
106. Lenchik L, Kiebzak GM, Blunt BA. What is the role of serial bone mineral density measurements in patient management? J Clin Densitom 2002;5 Suppl:S29-38.:S29-S38.
107. Bonnick SL. Current controversies in bone densitometry. Curr Opin Rheumatol 2002;14:416-20.
108. Deal CL. Using bone densitometry to monitor therapy in treating osteoporosis: pros and cons. Curr Rheumatol Rep 2001;3:233-9.
109. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 2000;11 Suppl 6:52-17.:52-17.
110. Stepan JJ. Prediction of bone loss in postmenopausal women. Osteoporos Int 2000; 11 Suppl 6:S45-54:S45-S54.
111. Miyao M, Morita H, Hosoi T, Kurihara H, Inoue S, Hoshino S et al. Association of methylenetetrahydrofolate reductase (MTHFR) polymorphism with bone mineral density in postmenopausal Japanese women. Calcif Tissue Int 2000:66:190-4.
112. Bode MK, Laitinen P, Risteli J, Uusimaa P, Juvonen T. Atherosclerosis, type 1 collagen cross-linking and homocysteine. Atherosclerosis 2000;152:531-2.
113. Lubec B, Fang-Kircher 5, Lubec T, Blom HJ, Boers GH. Evidence for McKusick's hypothesis of deficient collagen cross-linking in patients with homocystinuria. Biochim Biophys Acta 1996;1315:159-62.
114. Goerss JB, Kim CH, Atkinson EJ, Eastell R, O'Fallon WM, Melton LJ, III. Risk of fractures in patients with pernicious anemia. J Bone Miner Res 1992;7:573-9.
115. Reynolds TM, Marshall PD, Brain AM. Hip fracture patients may be vitamin B6 deficient. Controlled study of serum pyridoxal-5′-phosphate. Acta Orthop Scand 1992;63:635-8.
116. Melhus H, Michaelsson K, Holmberg L, Wolk A, Ljunghall S. Smoking, antioxidant vitamins, and the risk of hip fracture. J Bone Miner Res 1999;14:129-35.
117. Lumbers M, New SA, Gibson S, Murphy MC. Nutritional status in elderly female hip fracture patients: comparison with an age-matched home living group attending day centres. Br J Nutr 2001;85:733-40.
118. Bathum L, von Bornemann HJ, Christiansen L, Madsen JS, Skytthe A, Christensen K. Evidence for an association of methylene tetrahydrofolate reductase polymorphism C677T and an increased risk of fractures: results from a population-based Danish twin study. Osteoporos Int 2004;15:659-64.
119. Abrahamsen B, Madsen JS, Tofteng CL, Stilgren L, Bladbjerg EM, Kristensen SR et al. A common methylenetetrahydrofolate reductase (C677T) polymorphism is associated with low bone mineral density and increased fracture incidence after menopause: longitudinal data from the Danish osteoporosis prevention study. J Bone Miner Res 2003;18:723-9.
120. Villadsen MM, Bunger MH, Carstens M, Stenkjaer L, Langdahl BL. Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism is associated with osteoporotic vertebral fractures, but is a weak predictor of BMD. Osteoporos Int 2005;16: 411-6.
121. Jorgensen HL, Madsen JS, Madsen B, Saleh MM, Abrahamsen B, Fenger M, Lauritzen JB. Association of a common allelic polymorphism (C677T) in the methylene tetrahydrofolate reductase gene with a reduced risk of osteoporotic fractures. A case control study in Danish postmenopausal women. Calcif Tissue Int 2002;71:386-92.
122. Dhonukshe-Rutten RA, Lips M, de JN, Chin APM, Hiddink GJ, Van DM et al. Vitamin B-12 status is associated with bone mineral content and bone mineral density in frail elderly women but not in men. J Nutr 2003;133:801-7.
123. Dhonukshe-Rutten RA, Van DM, Schneede J, de Grout LC, van Staveren WA. Low bone mineral density and bone mineral content are associated with low cobalamin status in adolescents. Eur J Nutr 2005;44:341-7.
124. Tucker KL, Hannan MT, Qiao N, Jacques PF, Selhub J, Cupples LA, Kiel DP. Low Plasma Vitamin B(12) Is Associated With Lower BMD: The Framingham Osteoporosis Study. J Bone Miner Res 2005;20:152-8.
125. Stone KL, Bauer DC, Sellmeyer D, Cummings SR. Low serum vitamin B-12 levels are associated with increased hip bone loss in older women: a prospective study. J Clin Endocrinol Metab 2004;89:1217-21.
126. Abrahamsen B, Madsen JS, Tofteng CL, Stilgren L, Bladbjerg EM, Kristensen SR et al. Are effects of MTHFR (C677T) genotype on BMD confined to women with low folate and riboflavin intake? Analysis of food records from the Danish osteoporosis prevention study. Bone 2005;36:577-83.
127. McLean RR, Karasik D, Selhub J, Tucker KL, Ordovas JM, Russo GT et al. Association of a common polymorphism in the methylenetetrahydrofolate reductase (MTHFR) gene with bone phenotypes depends on plasma folate status. J Bone Miner Res 2004;19:410-8.
128. Li M, Lau EM, Woo J. Methylenetetrahydrofolate reductase polymorphism (MTHFR C677T) and bone mineral density in Chinese men and women. Bone 2004;35:1369-74.
129. Macdonald HM, McGuigan FE, Fraser WD, New SA, Ralston SH, Reid DM. Methylenetetrahydrofolate reductase polymorphism interacts with riboflavin intake to influence bone mineral density. Bone 2004;35:957-64.
130. Masse PG, Boskey AL, Ziv I, Hauschka P, Donovan SM, Howell DS, Cole DE. Chemical and biomechanical characterization of hyperhomocysteinemic bone disease in an animal model. BMC Musculoskelet Disord 2003;20;4:2.
131. Herrmann M, Widmann T, Colaianni G, Colucci S, Zallone A, Herrmann W. Increased osteoclast activity in the presence of increased homocysteine concentrations. Clin Chem 2005;51:2348-53.
132. Chenu C, Serre CM, Raynal C, Burt-Pichat B, Delmas PD. Glutamate receptors are expressed by bone cells and are involved in bone resorption. Bone 1998;22:295-9.
133. Espinosa L, Itzstein C, Cheynel H, Delmas PD, Chenu C. Active NMDA glutamate receptors are expressed by mammalian osteoclasts. J Physiol 1999;518:47-53.
134. Itzstein C, Espinosa L, Delmas PD, Chenu C. Specific antagonists of NMDA receptors prevent osteoclast sealing zone formation required for bone resorption. Biochem Biophys Res Commun 2000;268:201-9.
135. Itzstein C, Cheynel H, Burt-Pichat B, Merle B, Espinosa L, Delmas PD, Chenu C. Molecular identification of NMDA glutamate receptors expressed in bone cells. J Cell Biochem 2001;82: 134-44.
136. Merle B, Itzstein C, Delmas PD, Chenu C. NMDA glutamate receptors are expressed by osteoclast precursors and involved in the regulation of osteoclastogenesis. J Cell Biochem 2003;90: 424-36.
137. Brown, A. T, Chen, H., Zhang, X., and Moursi, M. M. Homocystein induces NADPH oxidase expression in rat vascular smooth muscle cells:role of NMDA receptor and PKC-epsilon. Clin Chem Lab Med 43[3], A27. 1-4-2005. Ref Type: Journal (Full)
138. Carmel R, Lau KH, Baylink DJ, Saxena S, Singer FR. Cobalamin and osteoblast-specific proteins. N Engl J Med 1988; 319:70-5.
139. Kim GS, Kim CH, Park JY, Lee KU, Park CS. Effects of vitamin B12 on cell proliferation and cellular alkaline phosphatase activity in human bone marrow stromal osteoprogenitor cells and UMR 106 osteoblastic cells. Metabolism 1996;45:1443-6.
140. Melton ME, Kochman ML. Reversal of severe osteoporosis with vitamin B12 and etidronate therapy in a patient with pernicious anemia. Metabolism 1994;43:468-9.
141. Dodds RA, Catterall A, Bitensky L, Chayen J. Abnormalities in fracture heating induced by vitamin B6-deficiency in rats. Bone 1986;7:489-95.
142. Maggio D, Barabani M, Pierandrei M, Polidori MC, Catani M, Mecocci P et al. Marked decrease in plasma antioxidants in aged osteoporotic women: results of a cross-sectional study. J Clin Endocrinol Metab 2003;88:1523-7.
143. Basu S, Michaelsson K, Olofsson H, Johansson S, Melhus H. Association between oxidative stress and bone mineral density. Biochem Biophys Res Common 2001;19;288:275-9.
144. Morton DJ, Barrett-Connor EL, Schneider DL. Vitamin C supplement use and bone mineral density in postmenopausal women. J Bone Miner Res 2001;16:135-40.
145. Bai XC, Lu D, Bai J, Zheng H, Ke ZY, Li XM, Luo SQ. Oxidative stress inhibits osteoblastic differentiation of bone cells by ERK and NF-kappaB. Biochem Biophys Res Common 2004: 314:197-207.
146. Garrett IR, Boyce BF, Oreffo RO, Bonewald L, Poser J, Mundy GR. Oxygen-derived free radicals stimulate osteoclastic bone resorption in rodent bone in vitro and in vivo. J Clin Invest 1990;85:632-9.
147. Mody N, Parhami F, Sarafian TA, Demer LL. Oxidative stress modulates osteoblastic differentiation of vascular and bone cells. Free Radic Biol Med 2001;31:509-19.
148. Masse PG, Rimnac CM, Yamauchi M, Coburn SP, Rucker RB, Howell DS, Boskey AL. Pyridoxine deficiency affects biomechanical properties of chick tibial bone. Bone 1996;18:567-74.
149. Lubec B, Fang-Kircher S, Lubec T, Blom HJ, Boers GH. Evidence for McKusick's hypothesis of deficient collagen cross-linking in patients with homocystinuria. Biochim Biophys Acta 1996;1315:159-62.
150. Lees S, Eyre DR, Barnard SM. BAPN dose dependence of mature crosslinking in bone matrix collagen of rabbit compact bone: corresponding variation of sonic velocity and equatorial diffraction spacing. Connect Tissue Res 1990;24:95-105.
151. Raposo B, Rodriguez C, Martinez-Gonzalez J, Badimon L. High levels of homocysteine inhibit lysyl oxidase (LOX) and down-regulate LOX expression in vascular endothelial cells. Atherosclerosis 2004;177:1-8.
152. Hill CH, Mecham R, Starcher B. Fibrillin-2 defects impair elastic fiber assembly in a homocysteinemic chick model. J Nutr 2002;132:2143-50.
153. Liu G, Nellaiappan K, Kagan HM. Irreversible inhibition of lysyl oxidase by homocysteine thiolactone and its selenium and oxygen analogues. Implications for homocystinuria. J Biol Chem 1997;19;272:32370-7.
154. Levene CI, Sharman DF, Callingham BA. Inhibition of chick embryo lysyl oxidase by various lathyrogens and the antagonistic effect of pyridoxal. Int Exp Pathol 1992;73:613-24.
155. Zou CG, Banerjee R. Homocysteine and redox signaling. Antioxid Redox Signal 2005;7:547-59.
156. Weiss N, Heydrick SJ, Postea O, Keller C, Keaney JF, Jr., Loscalzo J. Influence of hyperhomocysteinemia on the cellular redox state - impact on homocysteine-induced endothelial dysfunction. Clin Chem Lab Med 2003;41:1455-61.
157. Perna AF, Ingrosso D, De Santo NG. Homocysteine and oxidative stress. Amino Acids 2003;25:409-17.
158. Perna AF, Ingrosso D, Lombardi C, Acanfora F, Satta E, Cesare CM et al. Possible mechanisms of homocysteine toxicity. Kidney Int Suppl 2003;S137-S140.
159. Schroecksnadel K, Frick B, Wirleitner B, Winkler C, Schennach H, Fuchs D. Moderate hyperhomocysteinemia and immune activation. Curr Pharm Biotechnol 2004;5:107-18.
160. Rodrigo R, Passalacqua W, Araya J, Orellana M, Rivera G. Implications of oxidative stress and homocysteine in the pathophysiology of essential hypertension. J Cardiovasc Pharmacol 2003; 42:453-61.
161. Byrne JA, Grieve DJ, Cave AC, Shah AM. Oxidative stress and heart failure. Arch Mal Coeur Vaiss 2003;96:214-21.
162. Siems W, Quast S, Carluccio F, Wiswedel I, Hirsch D, Augustin W et al. Oxidative stress in chronic renal failure as a cardiovascular risk factor. Clin Nephrol 2002;58 Suppl 1:S12-9:S12-S19.
163. Searles CD. The nitric oxide pathway and oxidative stress in heart failure. Congest Heart Fail 2002;8:142-7, 155.
164. Sorescu D, Griendling KK. Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure. Congest Heart Fail 2002;8:132-40.
165. Wollert KC, Drexler H. Regulation of cardiac remodeling by nitric oxide: focus on cardiac myocyte hypertrophy and apoptosis. Heart Fail Rev 2002;7:317-25.
166. McFarlane SI, Muniyappa R, Shin JJ, Bahtiyar G, Sowers JR. Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link? Endocrine 2004;23:1-10.